Redmile Group’s Array Biopharma Inc ARRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-8,752,254
| Closed | -$405M | – | 90 |
|
|
2019
Q2 | $405M | Sell |
8,752,254
-2,218,264
| -20% | -$62.3M | 11.47% | 1 |
|
|
2019
Q1 | $267M | Sell |
10,970,518
-5,488,610
| -33% | -$114M | 7.83% | 1 |
|
|
2018
Q4 | $235M | Buy |
16,459,128
+552,448
| +3% | +$8.38M | 9.43% | 1 |
|
|
2018
Q3 | $242M | Sell |
15,906,680
-71,900
| -0.4% | -$1.1M | 7.44% | 1 |
|
|
2018
Q2 | $268M | Sell |
15,978,580
-1,245,848
| -7% | -$19.8M | 9.11% | 1 |
|
|
2018
Q1 | $281M | Sell |
17,224,428
-1,889,436
| -10% | -$30.3M | 10.85% | 1 |
|
|
2017
Q4 | $245M | Buy |
19,113,864
+1,557,278
| +9% | +$17.7M | 10.64% | 1 |
|
|
2017
Q3 | $216M | Buy |
17,556,586
+1,462,800
| +9% | +$13.6M | 10.65% | 1 |
|
|
2017
Q2 | $135M | Buy |
16,093,786
+3,327,924
| +26% | +$27.2M | 8.2% | 1 |
|
|
2017
Q1 | $114M | Sell |
12,765,862
-3,852,914
| -23% | -$41M | 7.41% | 1 |
|
|
2016
Q4 | $146M | Sell |
16,618,776
-39,296
| -0.2% | -$289K | 12.59% | 1 |
|
|
2016
Q3 | $112M | Sell |
16,658,072
-2,492,578
| -13% | -$9.64M | 8.94% | 1 |
|
|
2016
Q2 | $68.2M | Hold |
19,150,650
| – | – | 6.51% | 1 |
|
|
2016
Q1 | $56.5M | Buy |
19,150,650
+1,300,000
| +7% | +$3.9M | 5.78% | 5 |
|
|
2015
Q4 | $75.3M | Buy |
17,850,650
+100,140
| +0.6% | +$457K | 5.64% | 4 |
|
|
2015
Q3 | $80.9M | Buy |
17,750,510
+4,126,890
| +30% | +$24.5M | 6.13% | 3 |
|
|
2015
Q2 | $98.2M | Buy |
13,623,620
+498,026
| +4% | +$3.68M | 8.05% | 1 |
|
|
2015
Q1 | $96.7M | Buy |
13,125,594
+1,267,300
| +11% | +$9.02M | 8.69% | 1 |
|
|
2014
Q4 | $56.1M | Buy |
11,858,294
+3,516,249
| +42% | +$13.9M | 6.11% | 2 |
|
|
2014
Q3 | $29.8M | Buy |
8,342,045
+256,100
| +3% | +$1.01M | 3.44% | 9 |
|
|
2014
Q2 | $36.9M | Buy |
8,085,945
+3,203,015
| +66% | +$13.2M | 4.47% | 3 |
|
|
2014
Q1 | $22.9M | Buy |
4,882,930
+422,242
| +9% | +$2.12M | 2.74% | 11 |
|
|
2013
Q4 | $22.3M | Buy |
4,460,688
+791,095
| +22% | +$4.31M | 2.76% | 10 |
|
|
2013
Q3 | $22.8M | Sell |
3,669,593
-1,099,775
| -23% | -$6.53M | 3.44% | 11 |
|
|
2013
Q2 | $21.7M | Buy |
+4,769,368
| New | +$25.7M | 3.82% | 9 |
|
Other funds holding ARRY
Redmile Group's ARRY Position: Q3 2019 in Review
Redmile Group sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 8,752,254 shares — an estimated $405M sold.
Redmile Group first reported a position in ARRY in Q2 2013 and held it in 25 quarters. The position peaked at $405M in Q2 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.
- Redmile Group reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
- Redmile Group sold 8,752,254 Array Biopharma Inc shares in Q3 2019, an estimated $405M.
- Redmile Group first reported a position in Array Biopharma Inc in Q2 2013 and held it in 25 quarters.
- Redmile Group's Array Biopharma Inc position peaked at $405M in Q2 2019.
- 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.
Based on Redmile Group's 13F filing for Q3 2019, filed 14 Nov 2019.